Search Results - "Rezai, Keyvan"

PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.

Authors: Guerin, Mathilde Rezai, Keyvan Isambert, Nicolas et al.

Source: European Journal of Cancer. Nov2017, Vol. 86, p28-36. 9p.

A single-dose PK study of onapristone including the effect of food on absorption.

Authors: Rezai, Keyvan Chassard, Didier Denot, Caroline et al.

Source: Cancer Chemotherapy & Pharmacology. Jul2015, Vol. 76 Issue 1, p171-177. 7p.

Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients.

Authors: Rezai, Keyvan Urien, S. Isambert, N. et al.

Source: Cancer Chemotherapy & Pharmacology. Dec2011, Vol. 68 Issue 6, p1529-1536. 8p.

Application of an Environmental Monitoring to Assess the Practices and Control the Risk of Occupational Exposure to Cyclophosphamide in Two Sites of a French Comprehensive Cancer Center.

Authors: Acramel, Alexandre Fouque, Julien Blondeel-Gomes, Sandy et al.

Source: Annals of Work Exposures & Health. Nov2022, Vol. 66 Issue 9, p1215-1223. 9p.

Subjects: Hospitals, Professional practice, Environmental monitoring, Scientific observation, Blood vessels, Liquid chromatography, Medical equipment contamination, Occupational exposure, Antineoplastic agents, Intravenous therapy equipment, Risk assessment, Cyclophosphamide, Mass spectrometry, Descriptive statistics, Automation, Drug adulteration, Collection & preservation of biological specimens, Sterilization (Disinfection), Dosage forms of drugs, Personnel management, Medical equipment

Geographic Terms: France

Insights into the cellular pharmacological properties of the BET-inhibitor OTX015/MK-8628 (birabresib), alone and in combination, in leukemia models.

Authors: Astorgues-Xerri, Lucile Vázquez, Ramiro Odore, Elodie et al.

Source: Leukemia & Lymphoma. Dec2019, Vol. 60 Issue 12, p3067-3070. 4p.

Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers.

Authors: Cottu, Paul H. Bonneterre, Jacques Varga, Andrea et al.

Source: PLoS ONE. 10/10/2018, Vol. 13 Issue 10, p1-16. 16p.

TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients.

Authors: Vicier, Cecile Sfumato, Patrick Isambert, Nicolas et al.

Source: European Journal of Cancer. Dec2021, Vol. 159, p205-214. 10p.

A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial).

Authors: Campone, Mario Bachelot, Thomas Treilleux, Isabelle et al.

Source: European Journal of Cancer. Nov2021, Vol. 158, p169-180. 12p.

Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP.

Authors: Baudry, E. Huguet, S. Couderc, A. L. et al.

Source: Cancer Chemotherapy & Pharmacology. Apr2019, Vol. 83 Issue 4, p775-785. 11p.

Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer.

Authors: Bernadou, Guillemette Campone, Mario Merlin, Jean‐Louis et al.

Source: British Journal of Clinical Pharmacology. May2016, Vol. 81 Issue 5, p941-948. 8p. 2 Charts, 3 Graphs.

Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies.

Authors: Kurzrock, Razelle Goel, Sanjay Wheler, Jennifer et al.

Source: Cancer (0008543X). Dec2012, Vol. 118 Issue 24, p6144-6151. 8p.

Development of potent dual PDK1/AurA kinase inhibitors for cancer therapy: Lead-optimization, structural insights, and ADME-Tox profile.

Authors: Sestito, Simona Bacci, Andrea Chiarugi, Sara et al.

Source: European Journal of Medicinal Chemistry. Dec2021, Vol. 226, pN.PAG-N.PAG. 1p.

Single radio UHPLC analysis for the quality control of technetium-99m radiolabelled radiopharmaceuticals.

Authors: Schmitt, Camille Fouque, Julien Huguet, Samuel et al.

Source: Applied Radiation & Isotopes. Oct2021, Vol. 176, pN.PAG-N.PAG. 1p.

Acetalax and Bisacodyl for the Treatment of Triple-Negative Breast Cancer: A Combined Molecular and Preclinical Study.

Authors: Reinhold WC Marangoni E Elloumi F et al.

Source: Cancer research communications [Cancer Res Commun] 2025 Feb 01; Vol. 5 (2), pp. 375-388.

Publication Type: Journal Article; Research Support, N.I.H., Intramural

Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9918281580506676 Publication Model: Print Cited Medium: Internet ISSN: 2767-9764 (Electronic) Linking ISSN: 27679764 NLM ISO Abbreviation: Cancer Res Commun Subsets: MEDLINE

A first-in-class Wiskott-Aldrich syndrome protein activator with antitumor activity in hematologic cancers.

Authors: Spriano F Sartori G Sgrignani J et al.

Source: Haematologica [Haematologica] 2024 Nov 01; Vol. 109 (11), pp. 3602-3614. Date of Electronic Publication: 2024 Nov 01.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Ferrata Storti Foundation Country of Publication: Italy NLM ID: 0417435 Publication Model: Electronic Cited Medium: Internet ISSN: 1592-8721 (Electronic) Linking ISSN: 03906078 NLM ISO Abbreviation: Haematologica Subsets: MEDLINE

Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

Authors: Marret G Isambert N Rezai K et al.

Corporate Authors: Marret G Isambert N Rezai K et al.

Source: Investigational new drugs [Invest New Drugs] 2021 Dec; Vol. 39 (6), pp. 1641-1648. Date of Electronic Publication: 2021 Jul 28.

Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE

Targeting Adrenomedullin in Oncology: A Feasible Strategy With Potential as Much More Than an Alternative Anti-Angiogenic Therapy.

Authors: Vázquez R Riveiro ME Berenguer-Daizé C et al.

Source: Frontiers in oncology [Front Oncol] 2021 Jan 06; Vol. 10, pp. 589218. Date of Electronic Publication: 2021 Jan 06 (Print Publication: 2020).

Publication Type: Journal Article; Review

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE

Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSé-ESMART Trial.

Authors: Bautista F Paoletti X Rubino J et al.

Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2021 Nov 10; Vol. 39 (32), pp. 3546-3560. Date of Electronic Publication: 2021 Aug 04.

Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't; Adaptive Clinical Trial

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.

Authors: Berenguer-Daizé C Astorgues-Xerri L Odore E et al.

Source: International journal of cancer [Int J Cancer] 2016 Nov 01; Vol. 139 (9), pp. 2047-55. Date of Electronic Publication: 2016 Jul 30.

Publication Type: Journal Article

Journal Info: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 0042124 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0215 (Electronic) Linking ISSN: 00207136 NLM ISO Abbreviation: Int J Cancer Subsets: MEDLINE

Phase I-II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAF ^V600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism.

Authors: Louveau B Resche-Rigon M Lesimple T et al.

Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Jul 15; Vol. 27 (14), pp. 3876-3883. Date of Electronic Publication: 2021 May 04.

Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE